Next-generation sequencing cardiovascular gene panel testing in adults with isolated dilated cardiomyopathy achieved a final diagnostic yield of 20.7% after variant reanalysis.
Observational (n=169)
No
Next-generation sequencing cardiovascular gene panels provide a diagnostic yield of 20.7% in adult patients with isolated dilated cardiomyopathy, predominantly identifying TTN variants.
Background/Objectives: Dilated cardiomyopathy is a heterogeneous disorder with a substantial genetic contribution from a variety of pathogenic variants. Hereditary isolated DCM is often caused by variants in genes encoding sarcomere proteins, as well as proteins involved in desmosomes or other cardiac cell functions. Identifying genetic causes improves our understanding of DCM pathophysiology, facilitates prognostic assessment, and enables more personalized disease management. Methods: We retrospectively analyzed genetic data from adult patients with a clinical diagnosis of isolated DCM evaluated at a Lithuanian tertiary university hospital between 2019 and 2024. All patients were tested with a next-generation sequencing cardiovascular gene panel. Results: We gathered 169 patients and initially reached a 16.0% (n = 27) genetic testing diagnostic yield. We performed all genetic variant reanalyses with the most current classification guidelines, and we found an additional eight positive cases. Our final diagnostic yield was 20.7% (n = 35). TTN was the most frequently affected gene (n = 30), whereas variants in BAG3 (n = 2), DSP (n = 1), LMNA (n = 1), and FLNC (n = 1) were rare. In total, 15 variants were novel—not described in the literature or databases. We did not observe significant clinical differences between patients with pathogenic variants and those without pathogenic variants. We expected a different clinical course with variants in genes like BAG3 or LMNA, but there were only a few cases. Conclusions: Genetic testing remains an important tool for confirming complex DCM cases and allows earlier disease management for relatives at risk.
Šukys et al. (Mon,) conducted a observational in Dilated cardiomyopathy (n=169). Next-generation sequencing cardiovascular gene panel was evaluated on Genetic testing diagnostic yield. Next-generation sequencing cardiovascular gene panel testing in adults with isolated dilated cardiomyopathy achieved a final diagnostic yield of 20.7% after variant reanalysis.